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Over the last decade, a signiﬁcant body of research has been developed around the inclusion of a metallocene moiety into known
antimalarial compounds. Ferroquine is the most successful of these compounds. Herein, we describe our contribution to metal-
loceneantimalarials.Ourapproachhassoughttointroducediversitysitesinthesidechainofferroquineinordertodevelopaseries
of ferroquine derivatives. The replacement of the ferrocenyl moiety with ruthenocene has given rise to ruthenoquine and a modest
series of analogues. The reaction of ferroquine and selected analogues with Au(PPh3)NO3, Au(C6F5)(tht), and [Rh(COD)Cl2]
has resulted in a series of heterobimetallic derivatives. In all cases, compounds have been evaluated for in vitro antiplasmodial
activity in both chloroquine-sensitive and chloroquine-resistant strains of Plasmodium falciparum. Preliminary structure-activity
relationships have been delineated.
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Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
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1. INTRODUCTION
The ongoing battle against malaria is far from over. In the
1950s and 1960s, there was a massive drive to try and erad-
icate malaria worldwide following the successful eradication
of the disease in the United States. The population at risk
from malaria was reduced to 10%. However, the banning of
dicophane (DDT) and the concurrent emergence of chloro-
quine resistance led to the collapse of this campaign. A quar-
terofacenturylater,over300millionclinicalcasesofmalaria
occur annually and over 40% of the world’s population is at
risk of contracting the disease. Of these cases, over one mil-
lionwillprovefatal[1].Thegreatesttragedyofmalariaisthat
90% of fatalities occur in sub-Saharan Africa, and the over-
whelming majority of those fatalities are children under the
age of 5. Malaria is still essentially a tropical disease, but con-
tinues to claim the title of one of the leading killers among
infectious diseases. The importance of developing new an-
tiplasmodial drugs cannot be overemphasised. The Roll Back
Malaria campaign which began in 1998 has yet to show a de-
crease in malaria mortality rates [2].
Over the last decade, there has been an increasing inter-
est in metal-containing antiplasmodials. This trend was in
part initiated by the successes of metal-containing antitu-
mour drugs such as cisplatin. In the 1980’s and 1990’s, in-
terest in coordination complexes of known chemotherapeu-
tic agents began to emerge [3, 4]. It was not long before co-
ordination complexes of chloroquine were synthesised and
evaluated for eﬃcacy against both chloroquine-sensitive and
chloroquine-resistant strains of P. falciparum [5–7]. It is not
surprising that antiplasmodial eﬃcacy proved to be some-
what dependent on both metal and ligand.
The incorporation of a metallocene into compounds
with medicinal application was rare prior to the 1980’s. The
low cytotoxicity of ferrocene, coupled with its lipophilicity
(logPoctanol/water = 3.28) and its electrochemical behaviour
(redox potential of the ferrocene/ferrocenium couple, E0 =
+0.400V versus SCE (Saturated Calomel Electrode)), sug-
gested that this compound could yield interesting results if
incorporated into a known drug [8]. Indeed there are sev-
eralreportedsuccessesofincreasedeﬃcacyofferrocenylana-
logues of known drugs. Ferrocifen, the ferrocenyl analogue
of tamoxifen, has shown antiproliferation eﬀects in both
hormone-dependent and hormone-independent tumours.
Tamoxifen and other established chemotherapeutic agents
fail to exhibit such antiproliferative eﬀects in both hormone-
dependent and hormone-independent cell lines [9].2 Metal-Based Drugs
N
1. t-BuLi, Et2O
2. DMF
NH2OH,HCl
NaOH,H2O,EtOH
LiAlH4
THF
95% 98% 84%
67 8
N
Fe Fe Fe Fe
5
O H2N
HO
N N N
Scheme1:Synthesisof[(N,N-dimethylamino)methyl]ferrocenecarboxaldehyde(6),and2-[(N,N-dimethylamino)methyl]ferrocenemethy-
lamine (8).
Ferroquine and other ferrocenyl chloroquine analogues
have been shown to be eﬃcacious in vitro in both chlo-
roquine-sensitive and chloroquine-resistant P. falciparum
across a variety of strains [10–12].
The purpose of this paper is to draw together some of
the research carried out within our laboratories in the ﬁeld
of metal-containing chloroquine derivatives. This research,
together with work published recently by other researchers,
will hopefully shed some light on the role of ferrocene in fer-
roquine and related compounds.
2. FERROQUINE ANALOGUES AND DERIVATIVES
Brocard and colleagues have developed a number of ferro-
cene-containing chloroquine analogues [10]. Ferrocene was
incorporated as an integral part of the side chain; as a ter-
minal component of the side chain; and bonded through the
quinoline nitrogen [11–13]. They have shown that incorpo-
ration of a ferrocenyl moiety as an integral part of the side
chainofchloroquinebetweenthetwonitrogenshadsuperior
eﬃcacy to other analogues in which the moiety was terminal
on the side chain or bonded to the quinoline nitrogen. Some
analogues of the compound were produced bearing diﬀerent
alkyl groups on the terminal tertiary nitrogen. They estab-
lished that the dimethylamino terminal group was superior
in eﬃcacy [10].
Building on this foundation, we decided to explore the
possibility of developing other analogues of ferroquine in
which a reactive secondary amine group between the quino-
line and ferrocenyl moieties would serve as a site for in-
troducing further chemical diversity. We reasoned that this
would facilitate the exploration of structure-activity rela-
tionships. The role of the length of the methylene spacer
between the two nitrogens in chloroquine analogues has
been shown to have an inﬂuence on eﬃcacy in chloroquine-
resistant strains of P. falciparum [14]. Krogstad and cowork-
ers have shown that aminoquinolines with short (2-3 car-
bons) and long (10–12 carbons) methylene side chains
are equipotent against chloroquine-sensitive, chloroquine-
resistant, and multidrug-resistant strains of P. falciparum.
Whilst aminoquinolines with side chains of intermediate
length (4–8 carbons) showed eﬃcacy against chloroquine-
sensitive strains of P. falciparum, they showed a signiﬁcant
decrease in eﬃcacy against chloroquine-resistant strains of P.
falciparum[15].Forthisreason,wedecidedtoexplorethein-
ﬂuence of chain length on ferroquine analogues. The parallel
series of urea derivatives was also synthesised and evaluated
at the same time. The introduction of structural diversity via
the urea functionality is a well-established strategy in the de-
velopment of new biologically active compounds [16].
Synthesis of the ferroquine-type compounds was a-
chieved via the synthetic strategy shown in Schemes 1–3.
The reaction of 5 with n-butyllithium gave the desired prod-
uct in a reasonable yield (70%) [10]. However, the use of
tert-butyllithium had the eﬀect of reducing the reaction time
a n di m p r o v i n gt h ey i e l d[ 17]. The presence of the dimethy-
laminomethyl substituent on the ferrocene results in a high
regioselectivity for the 1,2-disubstituted product 6.
Ferroquine (2) was synthesised from 2-[(N,N-dim-
ethylamino)methyl] ferrocenemethylamine (8) and 4,7-di-
chloroquinoline. The published procedure uses dichloro-
methane and brine for the workup, in order to extract the
product from 1-methylpyrrolidinone [10]. We favoured the
use of ethyl acetate rather than dichloromethane as it was
more time eﬃcient. This had little impact on the moderate
yield of the reaction (53%).
Synthesis of compound 10 was achieved from 4,7-di-
chloroquinoline and the appropriate 1,n-alkyldiamine. The
two starting materials were simply reacted together in the
melt to form the product [18]. Compound 10 was then re-
acted with the ferrocenecarboxaldehyde (6) in methanol, to
form the imine (Schiﬀ base) which was then reduced in situ
with sodium borohydride to deliver compound 3 which was
inturnreactedwithphenylisocyanateindichloromethaneat
r o o mt e m p e r a t u r e( s e eS c h e m e3).
Consistent with previous observations [15, 16], the
length of the methylene spacer was found to have an inﬂu-
ence on antiplasmodial activity. In the chloroquine-sensitive
D10 strain, the longer the methylene spacer, the lower the
eﬃcacy. A distinguishable pattern was not quite so clear in
thechloroquine-resistantK1strain,butthemethylenespacer
length appeared to have an impact on eﬃcacy with com-
pound 3b (3-carbon spacer) showing the greatest eﬃcacy
[19]. For the urea derivatives, the chain length made no sig-
niﬁcant diﬀerence to eﬃcacy in D10, but a decrease in eﬃ-
cacy with an increase in the length of the methylene spacer
was observed in the K1 strain [19].
Giventhedistinctiveredoxchemistryofferrocene,wede-
cided to establish the electrochemical behaviour of the ana-
logues we had synthesised (see Table 2). It was postulated
that the half-wave potential E1/2 or ΔE value could provide
a cheap and quick method of screening for potential bi-
ological activity if this could be correlated to the in vitro
antiplasmodial activity. Unfortunately, no discernable trendM. A. L. Blackie and K. Chibale 3
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Scheme 3: Synthesis of ferroquine analogues (3a–d) and urea derivatives (4a–d).
was observed relating either of these values with in vitro ef-
ﬁ c a c yi ne i t h e rs t r a i no fP. falciparum.H o w e v e r ,i tw a sn o t e d
that the presence of the reactive secondary amine centre had
amark edeﬀectontheredoxchemistryoftheferrocenylmoi-
ety. Ferroquine exhibits a fully reversible one-electron oxida-
tion. The curve is similar to that of ferrocene (see Figure 2)
although the ferrocenyl moiety in ferroquine is signiﬁcantly
more diﬃcult to oxidise (E1/2 for FQ = 147; E1/2 for Fc = 79).
Compounds 3a–d showed, at best, a quasireversible ox-
idation. The cathodic peak current was signiﬁcantly smaller
than the anodic peak current (see Figure 2). The ease of re-
versibility of oxidation increases with an increase in carbon
chain length, as demonstrated by the decrease in ΔEp val-
ues (see Table 2). A fully reversible one-electron oxidation
requires a peak separation, ΔEp, of 70–90mV. In compounds
4a–d, the reversibility of the one-electron oxidation event in
the ferrocenyl moiety was restored. As with ferroquine, these
compounds are signiﬁcantly more diﬃcult to oxidise than
ferrocene, as demonstrated by the increase in half-wave po-
tential E1/2 values (see Table 2).
3. RUTHENOQUINE ANALOGUES
The chemistry of ferrocene is similar to the chemistry of
ruthenocene. In order to begin to probe the role of ferrocene
in ferroquine derivatives, we reasoned that it would be of
interest to synthesise the ruthenocene analogues of selected
derivatives (see Figure 3). The antiproliferative properties of
ferrocifen and its ruthenocene analogue have proven quite
diﬀerent. This diﬀerence in eﬃcacy has been attributed to
the stability of the ferrocenium ion relative to the ruthenoce-
nium ion. The presence of the ferrocenium ion allows for
a change in chemical reactivity at another point in the
molecule as a result of the highly conjugated system present
in the ferrocifen molecule. The instability of the ruthenoce-
nium ion does not allow for this change in chemical reactiv-
ity [9]. It is clear that a similar through-bond eﬀect is not
available in ferroquine or ruthenoquine as there is no con-
jugation accessible to the metallocene moiety in these com-
pounds. However, it was thought that some insight into the
role of ferrocene could be gained by examining the biological
activity of the ruthenocene analogues.4 Metal-Based Drugs
Table 1: In vitro antiplasmodial activities of ferroquine analogues.
41.86 ±1.25
41.7 ±2.6
51.37 ±3.85
61.16 ±1.53
86.92 ±7.3
21.35 ±1.99
16.2 ±0.54
16.74 ±4.25
19.01 ±6.24
125.38 ±4.53
73.46 ±6.4
36.93 ±1.7
111.5 ±12.9
81.39 ±5.57
37.5 ±7.35
47.41 ±2.41
75.23 ±8.49
110.2 ±9.46
2
3
4
6
2
3
4
6
CQ
3a
3b
3c
3d
4a
4b
4c
4d
O
O
O
O
HN
HN
HN
HN
H
H
H
H
D10 (CQS)
IC50 (nM)
K1 (CQR)
IC50 (nM)
Compound n
Reactive
secondary
amine
substituent
HN
Cl
N
N
1 chloroquine
(a)
N
Cl
Fe
N
H
N
2 ferroquine
(b)
N
H
N
H
n
N
Fe
N
Cl
3a–d
(c)
N N
H
N
Cl
n
NH Fe
N
O
4a–d
(d)
Figure 1: Structure of ferroquine analogues.
It was envisioned that a similar synthetic strategy could
be employed to synthesise the compounds 2Ru and 3aRu,
as had been used for the ferrocene analogues and de-
s c r i b e di nS c h e m e s1–3. However, the ruthenocene sys-
tem proved more complicated [20]. Firstly, (N,N-dimethyl-
aminomethyl) ruthenocene is not commercially avail-
able and had to be synthesised using Eschenmoser’s salt
([CH2=NMe2]I) [21]. Secondly, in the ferrocenyl sys-
tem, high regioselectivity for the 1,2-disubstituted prod-
uct 6 is observed. In the ruthenocenyl system, when usingM. A. L. Blackie and K. Chibale 5
Table 2: Cyclic voltametry measurements on antimalarial ferroquine analogues.
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n-butyllithium to achieve deprotonation, signiﬁcant quanti-
tiesofthe1,1 -monoaldehyde11,andthedialdehyde12were
formed (see Scheme 4). Isolation of 11 led to the synthe-
sis of isoruthenoquine, 2 Ru,a n d3a Ru. It was later discov-
eredthattheuseoftert-butyllithiumaﬀords6-Ruexclusively.
However,bythisstage,2 Ru and3a Ru hadalreadybeensyn-
thesised and found to show antiplasmodial activity [21]. In
order to create a better comparison of the eﬃcacies of the
ferrocene and ruthenocene compounds, the 1,1 -ferrocenyl
derivatives were also synthesised. The synthesis of the 1,1 -
ferrocenecompoundsrequiredafairlylengthysynthetic pro-
cedure which is discussed in full elsewhere [22].
All compounds tested exhibited a good eﬃcacy in both
chloroquine-sensitive and chloroquine-resistant strains.
Consistent with previous ﬁndings, the addition of the
metallocene was advantageous in overcoming chloroquine
resistance. These results indicate that the 1,2-disubstituted
compounds (2Fe, 2Ru, 3aFe,a n d3aRu) are more eﬃcacious
than the 1,1 -disubstituted analogues (2 Fe, 2 Ru, 3a Fe,
and 3a Ru) in the chloroquine-resistant K1 strain. It has
not been established why this trend should be observed,
but the crystal structures of these compounds clearly show
that there is a signiﬁcant increase in distance between
the 4-aminoquinoline nitrogen and the terminal nitrogen
when moving from the 1,2- to 1,1 -disubstituted product
[21, 23]. It has been previously established that this distance
is signiﬁcant in the observed eﬃcacy of 4-aminoquinolines
[15, 16]. It is noteworthy that barring compounds 3a Fe
and 3a Ru, there is no signiﬁcant diﬀerence in eﬃcacy
between ferrocenyl and ruthenocenyl analogues. This may
suggest that the diﬀerence in redox chemistry and chemical
reactivity of these moieties is not a factor in the eﬃcacy of
these compounds. The observed eﬃcacy may be associated
with the lipophilicity or physical bulk of the metallocene
group.
Comparative studies on the behaviour of chloroquine
and ferroquine have led to the conclusion that the eﬀect
of shape, volume, lipophilicity, basicity, and electronic pro-
ﬁles of the ferrocenyl moiety leads to a modiﬁcation of the
pharmacological behaviour of the analogue [23]. It has yet6 Metal-Based Drugs
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Figure 2: Cyclic voltammograms of selected ferrocene, ferroquine, 3a,a n d4a.
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Figure 3: Ferrocene and ruthenocene analogues of ferroquine.
to be established which of these factors is most signiﬁcant.
In chloroquine-resistant strains of P. falciparum,at r a n s -
porter protein, P. falciparum chloroquine resistance trans-
porter (PfCRT), has been identiﬁed which allows the eﬄux
of chloroquine from the food vacuole. It has been noted that
ferroquine resistance cannot be induced under drug pres-
sure in the W2 strain of P. falciparum. This has led to the
conclusion that the bulky lipophilic ferrocene moiety over-
comes PfRCT resistance, thereby maintaining ferroquine in
the food vacuole. In addition, ferroquine retains all the fea-
turesthathavebeenidentiﬁedasnecessaryinthestructureof
chloroquine (see Figure 4)[ 23]. The similarity of behaviourM. A. L. Blackie and K. Chibale 7
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Figure 4: Proposed structure-activity relationships for ferroquine
[23].
of the ruthenoquine and ferroquine molecules opens an in-
teresting avenue of research. Ruthenium is known to be a
good contrasting agent in electron microscopy [24]. It is
reasonable, in the absence of data to the contrary, to pos-
tulate that the mechanism of action of ruthenoquine and
ferroquine is similar. The sites of accumulation of rutheno-
quine can be established easily using scanning electron mi-
croscopy. In mice infected with Plasmodium berghei Na n d
treated with ruthenoquine, the drug has been found to ac-
cumulate close to the malaria pigment and in the parasitic
membrane. Chloroquine exhibits no such accumulation in
the parasitic membrane [25]. It is possible that ferroquine
exhibits a similar pattern of accumulation to ruthenoquine,
althoughthishasyettobeestablished.Thereasonforthisac-
cumulation of ruthenoquine in the membrane has not been
ascertained, but it may well be associated with the increase in
lipophilicity aﬀorded by the metallocene moiety.
4. COORDINATION COMPLEXES
A number of transition metals have been used to form
coordination complexes of chloroquine. These coordina-
tion complexes have been shown to exhibit improved eﬃ-
Table 3: Results of in vitro antimalarial tests conducted on the
chloroquine-sensitive (D10) and chloroquine-resistant (K1) strains
of P. falciparum.
Compound D10 K1
IC50/nM IC50/nM
CQ·2H3PO4 23 352
2Fe 18 14
2Ru 19 13
2 Fe 19 49
2 Ru 25 29
3aFe 33 37
3aRu 20 20
3a Fe 16 65
3a Ru 34 127
cacy in both chloroquine-sensitive and chloroquine-resistant
strains of P. falciparum compared to chloroquine [6, 7, 26].
The [Ru(Cl)2(CQ)]2 dimeric complex showed considerably
better in vivo eﬃcacy than was expected on the basis of
the in vitro results [6] .T h es a m es t u d yr e p o r t st h a tb o t h
[Rh(COD)Cl]2 and RuCl2(DMSO)4 failed to exhibit any
antiplasmodial activity. As the metal complexes of chloro-
q u i n es h o w e di m p r o v e de ﬃcacy against both chloroquine-
sensitive and chloroquine-resistant strains of the parasite,
it was concluded that the coordination of a metal to the
quinoline nitrogen enhanced the eﬃcacy of chloroquine in
vitro. However, a decade after the advent of these and other
chloroquine-metal coordination complexes, the mode of ac-
tion of these complexes is still poorly understood. It has not
been established whether these complexes reach the site of
action intact or not. Furthermore, it has not been established
whether the inhibition of β-haematin formation is possi-
ble with the presence of a coordinated metal. This question
is relevant as it has been established that the 7-chloro-4-
aminoquinoline structure is crucial for this mode of action
in chloroquine [27].
Given that the ferroquine derivatives could give rise to
an analogous series of ferroquine coordination complexes,
we thought it would be interesting to examine the eﬀect of
coordination of a second metal. To our knowledge, no such
heterobimetallic coordination complexes of chloroquine had
been synthesised and tested for antiplasmodial eﬃcacy [28].
Four ligands (1–4),i nFigure 5, were selected for preliminary
comparative studies.8 Metal-Based Drugs
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Table 4: In vitro activity of coordination complexes and the
free 4-aminoquinoline ligands in chloroquine-sensitive (D10) and
chloroquine-resistant (K1) strains of P. falciparum.
Compound D10 (CQ sensitive) K1 (CQ resistant)
IC50(nM) IC50 (nM)
L1 37.10 570.0
[Au(L1)(PPh3)]NO3 21.09 61.53
[Au(C6F5)(L1)] 18.07 61.09
[Rh(Cl)(COD)(L1)] 21.50 81.31
L2 16.30 4.96
[Au(L2)(PPh3)]NO3 10.50 5.68
[Au(C6F5)(L2)] 10.08 3.96
[Rh(Cl)(COD)(L2)] 15.80 10.55
L3 11.30 12.56
[Au(L3)(PPh3)]NO3 33.27 33.89
[Au(C6F5)(L3)] 13.70 14.65
[Rh(Cl)(COD)(L3)] 202.00 597.59
L4 16.54 15.54
[Au(L4)(PPh3)]NO3 30.32 31.09
[Au(C6F5)(L4)] 23.36 12.92
[Rh(Cl)(COD)(L4)] 56.10 47.70
The results shown in Table 4 indicate that the chloro-
quine complexes [Au(CQ)(PPh3)]NO3,[ A u ( C 6F5)(CQ)],
and [Rh(Cl)(COD)(CQ)] all show comparable eﬃcacy to
chloroquine in the chloroquine-sensitive strain. In the
chloroquine-resistant strain, these complexes exhibit an eﬃ-
cacy7to9timesbetterthanchloroquine.However,itisnote-
worthythateﬃcacyofthesecompounds droppeduptothree
times in moving from sensitive to resistant strain suggest-
ing that some cross-resistance may occur. Unfortunately, the
metal complexes of the ferrocenyl-4-aminoquinolines did
notperformsowell.Atbest,additionofthesecondmetalhad
littleeﬀectontheeﬃcacyoftheparentligand(asinpentaﬂu-
orophenylgoldcomplexesof L2,L3,andL4),whilstatworst,
thereappearedtobeasigniﬁcantantagonisticeﬀect(asinthe
cyclooctadienerhodiumcomplexesof L3andL4).Whilstthe
reason for this antagonistic eﬀect was not explored, it was
noted that the presence of the second metal made the ferro-
cenyl moiety far more diﬃcult to oxidise. This was evidenced
by the increase in half-wave potential, E1/2, in the complexes
of L2 and L4 when compared with the free ligand. In the
case of L3, where no fully reversible one-electron oxidation
was observed, the signiﬁcant increase in cathodic peak po-
tential suggests that the ferrocenyl moiety is more diﬃcult to
oxidise. Once again we found no discernible correlation be-
tween redox activity and antiplasmodial eﬃcacy.
5. DISCUSSION
The ferrocenyl moiety has several characteristics which make
it a good addition to known drug molecules. Its lipophilicity,
electron density, relative thermal and chemical stability, and
interesting redox behaviour are all favourable in this respect.
We have shown that altering the structure of the ferroquine
analogue can have a signiﬁcant eﬀect on the redox behaviour
oftheferrocenylmoiety.However,thereisnodiscerniblecor-
relation between the diﬀerences in redox behaviour, whether
ease of oxidation or reversibility of oxidation, and the eﬃ-
cacy of a compound against either chloroquine-sensitive or
chloroquine-resistant strain of P. falciparum. It is worth not-
ing that ferrocene and ruthenocene have quite diﬀerent re-
doxchemistry.Theruthenocenylanalogueoftheantitumour
agentferrocifenhasbeenshowntohaveasigniﬁcantlydiﬀer-
ent range of eﬃcacy which is attributed principally to this
diﬀerence in redox chemistry and the eﬀect on the highly
conjugated molecule to which the metallocene is bonded.
No such diﬀerence in antiplasmodial eﬃcacy is observed
here between ferrocenyl and ruthenocenyl analogues of fer-
roquine. This, together with our cyclic voltammetric stud-
ies and the lack of correlation with antiplasmodial eﬃcacy,M. A. L. Blackie and K. Chibale 9
Table 5: Cyclic voltametry of gold triphenylphosphine complexes and the parent ligands.
Compound (a)Epa(mV) (b)Epa(mV) (c)E1/2(mV) Epa-Epc(mV)
L2 181 113 147 70
[Au(L2)(PPh3)]NO3 252 162 207 90
L3 150 30 — 120
[Au(L3)(PPh3)]NO3 294 186 — 108
L4 198 115 158 83
[Au(L4)(PPh3)]NO3 219 141 180 78
(a) anodic potential; (b)cathodic potential; (c)half wave potential (Epa + Epc)/2.
suggests that the redox behaviour of the metallocene is not a
signiﬁcant factor in the eﬃcacy of these compounds. Some
study of the redox chemistry of the ruthenoquine analogues
would be useful to determine the accuracy of this supposi-
tion.
The incorporation of a ferrocenyl moiety into chloro-
quine has yielded fruitful results in terms of overcoming
chloroquine resistance. Ferroquine continues to undergo
testing to ascertain its suitability as a candidate for full-scale
human clinical trials [8]. However, the results of incorpo-
ration of a ferrocenyl moiety into other known antimalar-
ial drugs such as meﬂoquine, quinine [29], or artemisinin
[30] have proved far less rewarding. This raises a question
as to whether there is any inherent antiplasmodial toxicity
associated with the ferrocenyl moiety. It may be that the
changes in lipophilicity and pKa values and other physico-
chemical eﬀects of the incorporation of the ferrocenyl moi-
ety into chloroquine are the primary factor in the enhanced
eﬃcacy of ferroquine. This may also explain the antagonis-
tic eﬀects exhibited by the heterobimetallic complexes of fer-
roquine and its analogues. The presence of the complexed
metal and associated ligands may have adverse eﬀects on the
inﬂuence of the ferrocenyl moiety.
The role of the ferrocenyl moiety in the ability of ferro-
quine to overcome chloroquine resistance has still not been
fully determined, although its role in overcoming PfCRT re-
sistanceseemssupportedbyexperimentalevidence[24].The
continuing biological success of ferroquine means that this
avenue of research must remain open and active. If we are
to overcome the problem of malaria in sub-Saharan Africa, a
potent, cheap alternative to chloroquine must be found.
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